Skip to main content

Table 3 Biomarkers for checkpoint inhibitors: prognostic (in italics) and predictive details

From: Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Ipilimumab Pembrolizumab
Lactate dehydrogenase Stage III-IVB/IVC
Relative lymphocyte counts (RLC) Lactate dehydrogenase (LDH)
Absolute eosinophil counts (AEC) Relative lymphocyte counts (RLC)
Absolute monocyte counts (AMC) Relative eosinophil counts (REC)
Tregs: unknown  
MDSC: unknown  
γδ T-cells: uncertain  
Increase CD4+ CD8+ T cell: uncertain